Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study
Gazzah, A., Bedard, P. L., Hierro, C., Kang, Y. -., Abdul Razak, A., Ryu, M. -., . . . Tabernero, … Read More
